cardiovascular disease

Riboflavin and Blood Pressure: Evidence Remains Uncertain Despite Genetic Promise

By MedXY 12/16/2025

Cochrane review shows uncertain effects of riboflavin on blood pressure, highlighting a need for larger and better-quality trials.

Cardiology Neurology news

Low-Dose Colchicine Reduces Myocardial Infarction and Stroke Risk in Cardiovascular Disease Patients

By MedXY 12/16/2025

A large meta-analysis shows colchicine can lower MI and stroke risk without raising serious adverse events, but GI side effects remain a concern.

Clinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news OB/GYN & Women's Health

Planetary Health Diet and Cardiometabolic Risk Reduction in Women with Gestational Diabetes: An Evidence-Based Review

By MedXY 12/15/2025

This review synthesizes evidence linking adherence to the Planetary Health Diet with reduced risks of myocardial infarction, type 2 diabetes, and improved weight management in women post-gestational diabetes, highlighting BMI's mediating role.

Cardiology Family Medicine & Nutrition news

EAT‑Lancet Diet and Recurrent Cardiovascular Events: Lower Stroke Risk and a Signal for Myocardial Infarction in Patients with Established CVD

By MedXY 12/03/2025

Two cohort analyses suggest greater adherence to the EAT‑Lancet diet is linked with lower recurrent non‑fatal vascular events—notably stroke—and that education and sex modify long‑term cardioprotective benefits of this sustainable, plant‑forward pattern.

Cardiology Diabetes & Endocrinology news

Underweight in Type 2 Diabetes Raises Cardiovascular Risk — Severe Leanness Carries Greater Risk Than Obesity

By MedXY 12/02/2025

A nationwide Korean cohort found that underweight patients with Type 2 diabetes—especially those with severe underweight—have higher cardiovascular risk than normal-weight and even some obese patients, underscoring the need to screen and manage malnutrition, sarcopenia, and frailty in diabetes care.

Cardiology news

Hormone Therapy for Hot Flashes: Safe and Effective for Women 50–59, Harm Signals After Age 70 — New WHI Secondary Analysis Clarifies Cardiovascular Risk by Age

By MedXY 11/18/2025

A WHI secondary analysis finds that oral conjugated estrogens (with or without MPA) relieve vasomotor symptoms in women 50–59 without clear ASCVD harm, but starting HT in women ≥70 is associated with increased atherosclerotic cardiovascular disease.

Cardiology news Public Health

Reduced Arsenic in Drinking Water Tied to Large Drops in Cancer and Cardiovascular Mortality

By MedXY 11/17/2025

A prospective cohort in Bangladesh found that declines in urinary arsenic were associated with substantially lower chronic-disease mortality—including cancer and cardiovascular deaths—supporting public-health efforts to reduce arsenic exposure from drinking water.

Cardiology Neurology news

Do Vascular Pathways Explain How Lifestyle Affects Dementia Risk? A Critical Look at the Evidence

By MedXY 11/09/2025

A scoping review found sparse and inconsistent mediation analyses assessing cardiovascular disease as the pathway linking lifestyle factors to cognition; evidence is tentative for physical activity but urgent, better-designed studies are needed.

Cardiology news Public Health

Early Life Sugar Restriction and Its Lasting Impact on Adult Cardiovascular Health: Insights from a Natural Experiment

By MedXY 10/31/2025

Exposure to sugar rationing during the first 1000 days after conception correlates with significantly reduced cardiovascular disease risk and improved cardiac function decades later, highlighting early nutritional influences on long-term heart health.

Cardiology Neurology news Specialties

Obicetrapib’s Role in Modulating Alzheimer’s Disease Biomarkers in Patients with Cardiovascular Disease: A Landmark Clinical Study

By MedXY 10/21/2025

Obicetrapib, a CETP inhibitor, lowers Alzheimer’s biomarkers like p-tau217 in ASCVD patients, especially ApoE4 carriers, suggesting a potential preventive strategy for high-risk individuals.

Cardiology Nephrology Specialties

Statin Therapy in Older Adults with Chronic Kidney Disease: Primary Prevention of Cardiovascular Disease and Safety Profile in Hypercholesterolemic Patients

By MedXY 10/20/2025

This study demonstrates that statin therapy effectively reduces cardiovascular risk and all-cause mortality in older adults with chronic kidney disease and hypercholesterolemia, without increasing major adverse events, even in very elderly patients.

Cardiology Hematology-Oncology news

Clonal Hematopoiesis in Older Adults: Implications for Cardiovascular Risk, Bleeding, and Aspirin Use

By MedXY 10/15/2025

This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for those with CHIP in primary prevention of cardiovascular events.

Cardiology Nephrology news

Enhancing Cardiovascular Health in Kidney Transplant Recipients: Updated Evidence on Physical Activity Interventions

By MedXY 10/12/2025

An updated meta-analysis of 23 RCTs reveals that physical activity improves cardiorespiratory fitness and HDL cholesterol in adult kidney transplant recipients, suggesting important cardiovascular benefits despite current study limitations.

Cardiology HIV/AIDS news Specialties

Early HIV Treatment and Cardiovascular Health: Insights from the START Study

By MedXY 10/09/2025

Early ART initiation in HIV-positive adults with high CD4+ counts shows no overall cardiovascular benefit, but reduced CVD events in women suggest potential sex-specific effects needing further study.

Cardiology Infectious Diseases news

Evaluating Cardiovascular-Focused Messaging to Enhance Influenza Vaccination Uptake in Diverse U.S. Populations

By MedXY 10/03/2025

A large randomized trial in the U.S. found no significant improvement in influenza vaccination rates with cardiovascular-focused messaging compared to usual care, despite prior positive findings in Denmark.

news Public Health Respiratory

Evaluating the 23-Valent Pneumococcal Polysaccharide Vaccine for Cardiovascular Event Prevention: Insights from a Landmark Randomized Trial

By MedXY 09/27/2025

A large randomized clinical trial demonstrated that the 23-valent pneumococcal polysaccharide vaccine (PPV23) did not significantly reduce fatal or nonfatal acute coronary syndrome and ischemic stroke among middle-aged adults at increased cardiovascular risk over seven years of follow-up.

Family Medicine & Nutrition Medical News news Specialties

Citrate: The New Molecular Key to Reversing Vascular Aging and Combating Cardiovascular Disease

By MedXY 09/14/2025

Recent research reveals that citrate, a natural compound found in citrus fruits, may significantly reverse vascular aging and reduce the risk of cardiovascular diseases by restoring mitochondrial function and vascular elasticity.

Cardiology Pediatrics Specialties

Early Childhood High Blood Pressure Predicts Premature Cardiovascular Mortality: Insights from a 50-Year Longitudinal US Cohort

By MedXY 09/07/2025

Elevated blood pressure at age 7 significantly increases the risk of premature cardiovascular mortality by mid-adulthood, underscoring the need for early-life blood pressure monitoring and intervention.

Cardiology Public Health Specialties

Enhanced Protection in Heart Failure: High-Dose Influenza Vaccine Outperforms Standard Dose in the DANFLU-2 Trial

By MedXY 09/06/2025

The DANFLU-2 trial reveals that high-dose influenza vaccine significantly reduces hospitalization for influenza and cardiovascular events in older adults, including those with heart failure, compared to the standard-dose vaccine.

Clinical Updates news Nursing & care Specialties

Stalking, Restraining Orders, and Cardiovascular Health Risks in Women: Insights from the Nurses’ Health Study II

By MedXY 09/06/2025

A 20-year prospective study reveals that experiences of stalking and obtaining restraining orders are linked to increased risk of cardiovascular events in women, emphasizing violence as a critical factor in cardiovascular disease prevention.